Eli Lilly (NYSE: LLY) to shed 10% stake after Scribe IPO
Rhea-AI Filing Summary
ELI LILLY & Co reported its initial beneficial ownership in Scribe Therapeutics, Inc. (SCTX) as a 10% owner. It holds 1,054,828 shares of Common Stock on a direct basis. The company states that, after the closing of Scribe Therapeutics' initial public offering, it will cease to be a 10% owner and will no longer have Section 16 reporting obligations.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
ELI LILLY & Co
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,054,828 shares (Direct)
Key Figures
Common Stock held: 1,054,828 shares
Holding entries reported: 1
Buy transactions: 0
+1 more
4 metrics
Common Stock held
1,054,828 shares
Directly owned Scribe Therapeutics Common Stock reported in the Form 3
Holding entries reported
1
Number of holding-line entries in the non-derivative table
Buy transactions
0
Number of reported purchase transactions in the transaction summary
Sell transactions
0
Number of reported sale transactions in the transaction summary
Key Terms
Section 16 reporting obligations, 10% Owner, initial public offering, beneficial ownership
4 terms
Section 16 reporting obligations regulatory
"will have no further Section 16 reporting obligations"
10% Owner regulatory
"will cease to be a 10% Owner"
initial public offering financial
"closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
beneficial ownership financial
"reported its initial beneficial ownership in Scribe Therapeutics"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What does Eli Lilly (LLY) report in this Form 3 regarding Scribe Therapeutics (SCTX)?
Eli Lilly reports its initial beneficial ownership position in Scribe Therapeutics as a 10% Owner, disclosing a direct holding of 1,054,828 shares of Common Stock as required under Section 16 for significant shareholders.
Will Eli Lilly (LLY) remain a 10% owner of Scribe Therapeutics (SCTX) after the IPO?
Eli Lilly states it will cease to be a 10% Owner after the closing of Scribe Therapeutics’ initial public offering. As a result, it indicates it will have no further Section 16 reporting obligations once that closing takes effect.
Does this Eli Lilly (LLY) Form 3 report any recent transactions in Scribe Therapeutics (SCTX) stock?
The Form 3 does not report any buy or sell transactions. It lists a holding entry showing 1,054,828 shares of Common Stock owned directly, serving as an initial statement of beneficial ownership rather than a record of trading activity.
What is the significance of Section 16 reporting for Eli Lilly’s stake in Scribe Therapeutics (SCTX)?
Section 16 requires 10% owners and insiders to report their holdings and certain trades. Eli Lilly notes that, after Scribe’s IPO closes and it ceases to be a 10% owner, it will have no further Section 16 reporting obligations related to this position.
AI-generated analysis. How Rhea-AI works. Not financial advice.
